UK - Celtic Therapeutics to invest up to $15m into Spirogen

Spirogen is pioneering the discovery and development of a unique class of low molecular weight sequence-specific DNA-interactive drugs designed to treat gene-mediated diseases. The company was founded in 2001 and is based in London.

The new funding will go towards the development of Spirogen's lead cancer drug, SG2000. The company expects to continue clinicial development of the drug in an upcoming National Cancer Institute-sponsored multi-centre Phase II study of SG2000 in resistant and refractory ovarian cancer.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland